Phase 1b/2 Disitamab Vedotin ADC (tubulin inhibitor) in advanced breast cancer

This open-label trial by Pfizer evaluates disitamab vedotin monotherapy in adults with metastatic or locally advanced breast cancer expressing various HER2 levels and hormone receptors. Participants receive an IV infusion every two weeks to assess safety, tolerability, and tumor response. The study investigates the HER2-directed antibody-drug conjugate’s ability to deliver a tubulin inhibitor, offering insights into a novel targeted therapy for patients who have progressed on prior treatments.